Yuri Maricich
Chief Tech/Sci/R&D Officer at PEAR THERAPEUTICS, INC.
Net worth: - $ as of 2024-01-30
Profile
Dr. Maricich leads the Clinical/Regulatory/Quality and Medical Affairs group at Pear Therapeutics as the Chief Medical Officer and Head of Development.
He leads and manages the development programs from Discovery/TPP stage, through Translational, Clinical Development, Regulatory submission and review as well as Medical Affairs.
In addition to overseeing subsequent pipeline programs across a broad-spectrum of disease areas (such as CNS/neuroscience, cardiovascular, and oncology), he led reSET (1st prescription digital therapeutic) and reSET-O (1st combination drug and software treatment) programs.
Dr. Maricich is a licensed, board-certified physician, investor, clinical developer and strategist.
He works to improve patient health and our healthcare system by investing in, advising, and providing leadership at innovative firms.
He has worked with and led successful teams and programs at Healthcare & Life Science/biotech (HLS) firms, including Corixa (acquired by GlaxoSmithKline), Xdynia (acquired by Cavion), Cavion (acquired by Jazz Pharmaceuticals), AWS, and Pear Therapeutics (1st FDA-cleared, clinically validated digital therapeutic to treat disease).
He founded a digital health firm while a med student that used AI and NLP to structure clinical data.
Dr. Maricich completed his education and training at Harvard University, the University of Washington, the University of Notre Dame, and the University of Virginia.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-02-14 | 94,333 ( 0.07% ) | - $ | 2024-01-30 |
Yuri Maricich active positions
Companies | Position | Start |
---|---|---|
PEAR THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Pear Therapeutics (US), Inc.
Pear Therapeutics (US), Inc. Packaged SoftwareTechnology Services Pear Therapeutics (US), Inc. develops and provides a platform that combines pharmaceutical preparations with scientifically validated software applications. It offers eFormulation, pharmaceutical-software combination products. The firm combines digital therapies with supplements, medical foods and pharmaceuticals to create more effective treatment solutions. The company was founded in 2013 by Corey M. McCann, Stephen Kennedy Smith and William Greene and is headquartered in Boston. MA. | Chief Tech/Sci/R&D Officer | - |
Angelini Ventures SpA
Angelini Ventures SpA Investment ManagersFinance Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy. | Consultant / Advisor | - |
Training of Yuri Maricich
University of Washington | Doctorate Degree |
Harvard Business School | Masters Business Admin |
University of Notre Dame | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
PEAR THERAPEUTICS, INC. | Health Technology |
Private companies | 2 |
---|---|
Pear Therapeutics (US), Inc.
Pear Therapeutics (US), Inc. Packaged SoftwareTechnology Services Pear Therapeutics (US), Inc. develops and provides a platform that combines pharmaceutical preparations with scientifically validated software applications. It offers eFormulation, pharmaceutical-software combination products. The firm combines digital therapies with supplements, medical foods and pharmaceuticals to create more effective treatment solutions. The company was founded in 2013 by Corey M. McCann, Stephen Kennedy Smith and William Greene and is headquartered in Boston. MA. | Technology Services |
Angelini Ventures SpA
Angelini Ventures SpA Investment ManagersFinance Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy. | Finance |
- Stock Market
- Insiders
- Yuri Maricich